technology platform
Molecular Technology Platform
The latest research technology of tumor initiating (stem) cells of the team has gradually transformed into the application technology of early diagnosis and prognosis of tumors, and has applied for a number of patents related to early diagnosis and treatment of tumors.
As a core scientific researcher, Dr. Li Chenwei confirmed for the first time in the world in 2007 that it has a high degree of tumorigenicity and has a cell phenotype of CD44 CD24 ESA pancreatic tumor initiating cells. This is the world's first isolated digestive system tumor initiating cells. Later, Dr. Li Chenwei discovered gastric cancer stem cells. Traditional cancer treatments often target tumor cells and miss tumor stem cells. This is why conventional treatments can shrink tumors, but most tumors will return. The study of tumor initiating cells and the development of drugs or methods targeting tumor initiating cells will greatly improve the efficiency of tumor treatment. Dr. Li's recent research interests focus on finding new drugs and individualized therapies that selectively target pancreatic, gastric and colorectal tumor-initiating cells. The projects with Dr. Chenwei Li include: Pfizer, Exelixi, Lilly and other new drugs and treatments for pancreatic cancer starting cells. These stem cell treatment programs for pancreatic cancer have achieved promising results and will bring huge commercial profits.
Ningbo Zhongyuan Biotechnology Co., Ltd.
15th Floor, Block A, 89 Cuibai Road, Haishu District, Ningbo City
Tel:+86 0574-87206227,+86 13905845087
Email:1409244836@qq.com
Guizhou Zhongyuan Biotechnology Co., Ltd.
11/F, Building B4, Zhihui Yunjin, No.2, Happy North Road, Wudang District, Guiyang City, Guizhou Province
Guizhou Zhongyuan Medical Technology Co., Ltd.
11/F, Building B4, Zhihui Yunjin, No.2, Happy North Road, Wudang District, Guiyang City, Guizhou Province